Bernard A. Fox, Co-founder, President, and CEO of UbiVac, shared a post on LinkedIn:
“It’s a WRAP! Another JP Morgan is in the books for me!
JPM2026 was my best JPM ever! People wanted to hear what UbiVac has done!
- 1st DarkGenome-derived CancerVaccine into patients.
- Completed NCI-funded Phase I/II – safety, formulation, MOA.
- Phase Ib – led by Rom Leidner and supported by Incyte, Providence Cancer Institute, and Ubivac – Tripled Response Rate (RR) and progression-free survival and doubled + overall survival – over historical controls – in HNSCC
- 400+ DarkAntigens/Cryptic peptides/NonCanonical proteins/cancer’s DarkMatter
- 1st in-human generated TCR to a DarkGenome target that is shared by NSCLC, HNSCC, and pancreatic cancer – maybe additional cancers.
- Plus more… Will talk about that at HSBC/AACR/CVC Cancer Vaccine meeting at the end of the month…
WHILE THE SCIENTIFIC EVIDENCE IS CRYSTAL CLEAR! Think the Merck – Epitopea and BioNTech SE – CureVac deals in 2025 may have generated some FOMO.
IN MY OPINION: THAT FEAR is very reasonable
There is now substantial interest from a number of players… The visionary leaders in pharma and biotech will make the next call.”
Proceed to the video attached to the post.
More posts featuring Bernard A. Fox.